A Dose-Escalation Study of R1507 [RO4858696] in Patients With Advanced Solid Tumours.
Latest Information Update: 31 Mar 2021
At a glance
- Drugs Teprotumumab (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 26 Mar 2021 Results of a population PK analysis using data from three clinical studies: NCT00400361, NCT01868997 and NCT03461211 published in the Clinical Pharmacokinetics
- 23 Sep 2020 Results assessing pharmacokinetics and exposure-response relationship of Teprotumumab in this and Phase 2 and 3 studies presented at the 2020 American College of Clinical Pharmacology Annual Meeting
- 14 May 2020 Results published in the Horizon Therapeutics plc Media Release.